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BACKGROUND: The objective of this study was to determine the effect of Medicaid expansion under the Patient Protection and 
Affordable Care Act (January 1, 2014) on the epidemiology of high-risk prostate-specific antigen (PSA) levels (≥20 ng/mL) at the time of 
prostate cancer (PCa) diagnosis. The authors hypothesized that better access to care would result in a reduction of high-risk features at 
diagnosis. METHODS: A retrospective cohort study was performed of 122,324 men aged <65 years who were diagnosed with PCa within 
the National Cancer Database. Difference-in-difference (DID) analyses adjusting for sociodemographic variables using linear regression 
compared PSA levels at diagnosis before expansion (2012-2013) and after expansion (2015-2016) between men residing in states that did 
or did not expand Medicaid. RESULTS: From 2012 to 2016, the proportion of men with PSA levels ≥20 ng/mL increased (from 18.9% to 
19.8%) in nonexpansion states and decreased (from 19.9% to 18.2%) in expansion states. Compared with men in nonexpansion states, men 
in expansion states experienced a decline in PSA ≥20 ng/mL (DID, −2.33%; 95% CI, −3.21% to −1.44%; P < .001). Accordingly, the propor-
tion of men presenting with high-risk disease decreased in expansion states relative to nonexpansion states (DID, −1.25%; 95% CI, −2.26% 
to 0.25%; P = .015). A similar statistically significant decrease in PSA levels ≥20 ng/mL was noted among black men (DID, −3.11%; 95% CI, 
−5.25% to 0.96%; P = .005). CONCLUSIONS: In Medicaid expansion states, there was an associated decrease in the proportion of young 
men presenting with PSA ≥20 ng/mL at the time of PCa diagnosis. These results suggest that Medicaid expansion improved access to 
PCa screening. Longer term data should assess oncologic outcomes. Cancer 2020;126:3229-3236. © 2020 American Cancer Society. 
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INTRODUCTION
Men without health insurance harbor a greater risk of metastases at the time of diagnosis of prostate cancer (PCa) com-
pared with the general population in the United States1 and present with higher levels of prostate-specific antigen (PSA) 
(a marker of disease severity).2 It has been demonstrated that uninsured patients have greater odds of presenting with 
advanced disease and experience worse cancer-specific survival compared with those with Medicaid.2,3 Therefore, 
increasing health insurance coverage through Medicaid expansion could result in improved cancer-specific outcomes.
Implementation of the Patient Protection and Affordable Care Act allowed states to expand Medicaid eligibility 
to cover a larger group of low-income Americans; 24 states and the District of Columbia had opted to expand by 
January 1, 2014. After expansion, states that had opted in saw an increase in rates of Medicaid coverage and a subse-
quent reduction in uninsured rates relative to states that did not expand.4 Previous studies have associated Medicaid 
expansion with an increase in cancer screening and a decrease in late-stage diagnoses for some.5-7 Because of the pro-
longed natural history of prostate cancer, it is not surprising that there were no decreases in late-stage PCa in the first 
year of expansion (2014).6 One way to detect improvements in PCa care is to assess PCa screening by measuring PSA 
levels before diagnosis. As noted in screening trials, PSA values ≥20 ng/mL are associated with a poor prognosis, and 
PSA-based PCa screening can reduce the number of men who present with high-risk PSA values before diagnosis.8,9 
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Thus declines in high-risk PSA values at the time of PCa 
diagnosis may precede a stage migration toward earlier 
disease and improvements in PCa oncologic outcomes.
In this context, we used a large national cancer reg-
istry in the United States that included data through the 
third year of Medicaid expansion (2016) to measure the 
association between Medicaid expansion and PSA level 
at the time of PCa diagnosis. We hypothesized that state-
wide Medicaid expansion would be associated with im-
provements in access to PCa screening, as determined by 
decreases in the proportion of men with PCa who pre-




The National Cancer Database (NCDB) is comprised of 
greater than 1500 hospitals accredited by the American 
College of Surgeons Commission on Cancer with data 
through 2016.10 On the basis of estimates from the American 
Cancer Society,11 the NCDB captured approximately 68% 
of all new PCa cases diagnosed in the United States in 2016 
(oliver.facs.org/BMPub/index.cfm) (for information on our 
analysis of Census data, see Supporting Methods).
Patients
We included all men who were diagnosed with PCa 
from 2012 (2 years before Medicaid expansion) through 
2016, excluding men who were diagnosed in 2014 
as a washout year. In addition, we included men aged 
≤64  years who resided in a state that either expanded 
Medicaid on January 1, 2014; expanded Medicaid after 
the study period (after December 31, 2016); or never 
expanded Medicaid (n = 132,976; 100%) (Fig. 1). We 
excluded men who had unknown data on regional educa-
tion (n = 1677; 1.3%) or income (n = 268; 0.2%). An 
additional 2847 men (2.1%) were excluded because of 
missing data on insurance type (insured or noninsured). 
Finally, in total, 5860 men (4.4%) were excluded because 
of missing data on cancer grade, stage, or PSA level at 
diagnosis. Thus, in total, 10,652 men (8%) who met in-
clusion criteria were excluded from our primary analyses.
FIGURE 1. Medicaid expansion is illustrated by state. Only states that expanded Medicaid on January 1, 2014 (expansion states), 
expanded Medicaid after December 31, 2016, or never expanded Medicaid (nonexpansion states) were included in this study. 
This map was generated with information on Medicaid expansion timing from the National Cancer Database data dictionary and 
from https://www.healt hinsu rance.org/medic aid/ (accessed October 9, 2019). The following states will expand or have expanded 
Medicaid since December 31, 2016: Idaho, Maine, Nebraska, Virginia, and Utah.
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Primary Exposures
Our main exposures of interest were year of diagnosis— 
pre-Medicaid expansion (2012-2013) versus post- 
Medicaid expansion (2015-2016)—and residence in states 
that expanded Medicaid on January 1, 2014 versus states 
that expanded Medicaid after the study period or never 
expanded Medicaid during the study period (Fig. 1). 
Other exposures considered in multivariable analyses are 
discussed in the Supporting Methods.
Outcomes
Our outcomes were based on changes in the annual 
proportion of measurements relative to measurements 
from 2012 and 2013 in states that expanded Medicaid. 
Our primary outcome was changes in the proportion 
of men presenting with PSA level ≥20  ng/mL at the 
time of diagnosis. A cutoff of 20 ng/mL was chosen for 
3 reasons.
First, PSA levels ≥20  ng/mL are considered by 
National Comprehensive Cancer Network (NCCN) cri-
teria and clinical series to be high-risk and associated with 
high-grade disease and a high likelihood of disease recur-
rence after optimal local treatment.12-14 In addition, in a 
large PCa screening trial, in the earlier years of screening, 
there were higher proportions of men being diagnosed with 
PSA ≥20 ng/mL, which was associated with worse sur-
vival.8 Second, in that same screening trial, declines in the 
percentage of men being diagnosed with PSA ≥20 ng/mL 
were noted only within 2 screening rounds, suggesting 
that it can serve as a marker of screening access in the 
few years after Medicaid expansion.8 Finally, the NCDB 
codes PSA values >99  ng/mL only as such; therefore, 
assessment of PSA as a continuous variable would not be 
possible.12
Secondary outcomes included changes in the propor-
tion of men diagnosed with intermediate-risk or low-risk 
disease (biopsy Gleason grade groups 1-3, PSA <20 ng/
mL, and clinical tumor classification 1-2 [cT1-cT2]) and 
high-risk disease (biopsy Gleason grade groups 4-5, PSA 
≥20 ng/mL, or cT3-cT4), as defined by the NCCN.12 
In addition, metastatic disease at diagnosis (clinical met-
astatic classification 1 [cM1] or clinical lymph node sta-
tus 1 [cN1] according to the American Joint Committee 
on Cancer AJCC Cancer Staging Manual, 7th edition15) 
and insurance coverage (yes vs no) for men with PCa was 
assessed.
Statistical Analyses
We compared the median age of patients from expansion 
and nonexpansion states using the Mann-Whitney U test 
and compared categorical variables using chi-square tests. 
Analyses simply comparing outcomes preintervention and 
postintervention would not account for temporal trends 
before the intervention or other external factors. Therefore, 
our primary and secondary outcomes were assessed using 
a difference-in-difference (DID) analysis,16 with patients 
residing in Medicaid expansion states serving as the inter-
vention group and those residing in nonexpansion states 
serving as controls. DID values were calculated as percent-
ages by performing linear regression analyses with an in-
teraction term between Medicaid expansion and time and 
multiplying by 100. Two separate dummy variables were 
created to represent time preintervention and postinter-
vention: 1) 2012 to 2013 versus 2015 to 2016, and 2) 
2012 to 2013 versus 2015 or 2016. To test our hypothesis 
and to avoid multiple testing, we would reject the null hy-
pothesis if there was statistical significance (P < .05) only 
when comparing 2012 to 2013 with 2015 to 2016 (for 
additional information on the use of the DID analysis, see 
Supporting Methods). Unadjusted annual rates for each 
outcome were displayed as percentages.
We performed an exploratory analysis by limiting our 
analyses to black men, a racial group with previously doc-
umented higher risks of PCa death and presentation with 
later stage disease.17 Additional univariable comparisons 
were made between patients who did and did not meet 
exclusion criteria, and we also performed a sensitivity anal-
ysis of our primary outcome, including excluded patients 
who had unknown dummy variables for all missing data. 
All analyses were conducted using Stata 13.0 (Stata Corp).
RESULTS
Cohort Characteristics
The cohort consisted of 65,954 men from nonexpan-
sion states and 56,370 men from expansion states (see 
Supporting Table 1). Over the entire study period, pa-
tients from expansion states were more likely to be white 
(74% vs 67%; P  <  .001) and more likely to have no 
comorbidities (84.4% vs 82.6%; P < .001). More patients 
in expansion states lived in regions of high median house-
hold income ($64,000 annually; 47% vs 29%; P < .001). 
Approximately 19% of the cohort presented with PSA 
levels ≥20  ng/mL at the time of diagnosis, and a high 
PSA level was associated with high-grade disease at biopsy 
(see Supporting Table 2).
Medicaid Expansion and PSA at Diagnosis
The unadjusted proportion of men with PSA ≥20 ng/mL 
increased from 18.9% to 19.8% during 2012 through 
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2016 in nonexpansion state, whereas this proportion 
decreased in expansions states from 19.9% to 18.2% 
(Fig. 2A; see Supporting Table 3). On the basis of the 
multivariable DID analysis, Medicaid expansion was as-
sociated with a 2.33% decrease (95% CI, 3.21%-1.44%; 
P < .001) in the proportion of men presenting with PSA 
≥20 ng/mL in expansion states relative to nonexpansion 
states from the pre-Medication expansion era (2012-
2013) to the post-Medicaid expansion era (2015-2016) 
(Table 1). The adjusted DID comparing year 3 of ex-
pansion (2016) versus the pre-Medicaid expansion era 
showed a decrease of 2.95% (95% CI, 4.03%-1.86%; 
P <  .001) in expansion states relative to nonexpansion 
states.
Similarly, adjusted DID analyses limited to black 
men revealed that expansion was associated with a de-
crease of 3.11% (95% CI, 5.25%-0.96%; P =  .005) in 
expansion states relative to nonexpansion states from the 
pre-Medicaid expansion era to the post-Medicaid expan-
sion era (Table 2). The adjusted DID comparing year 3 
of expansion alone with the pre-Medicaid expansion era 
showed a decrease of 4.51% (95% CI, 7.13%-1.88%; 
P  =  .001) in expansion states relative to nonexpansion 
states.
Medicaid Expansion and Risk Group at Diagnosis
Next, we sought to determine whether decreases in the 
proportion of men presenting with PSA levels ≥20 ng/
mL resulted in decreases among men categorized as hav-
ing a high risk of disease progression based on NCCN 
high-risk localized disease criteria at diagnosis.12 In ad-
justed DID analysis, expansion was associated with a sig-
nificant decrease in the proportion of high-risk disease 
at diagnosis in expansion states relative to nonexpansion 
states from the pre-Medicaid expansion era to the post-
Medicaid expansion era (−1.25%; 95% CI, −2.26% to 
0.25%; P =  .015) (Fig. 2A and Table 1; see Supporting 
Table 3). Among black men, the overall DID was not sta-
tistically significant (P =  .083) (Table 2). However, the 
adjusted DID comparing year 3 of expansion alone with 
the pre-Medicare expansion era did demonstrate a signifi-
cant decrease of 3.42% (95% CI, −6.25% to −0.59%; 
P  =  .018) in expansion states relative to nonexpansion 
states among black men.
FIGURE 2. (A-D) Unadjusted temporal trends in outcomes at diagnosis are illustrated among states that expanded and did not 
expand Medicaid. Error bars represent 95% confidence intervals. Vertical dashed lines demarcate the division between pre-Medicaid 
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On the basis of the above results, we surmised that 
decreases in high-risk localized disease would accom-
pany increases in the proportion of men presenting 
with NCCN intermediate-risk or low-risk PCa, which 
is associated with a greater likelihood of cure with local 
treatment.12 In adjusted DID analysis, expansion was 
associated with a nonsignificant increase in the propor-
tion of intermediate-risk or low-risk disease in expansion 
states relative to nonexpansion states from the pre- 
Medicaid expansion era to the post-Medicaid expansion 
era (0.99%; 95% CI, −0.07% to 2.05%; P  =  .067) 
(Fig. 2B and Table 1). However, the adjusted DID com-
paring year 3 of expansion alone with the pre-Medicaid 
expansion era showed a significant increase of 1.60% 
(95% CI, 0.30%-2.91%; P = .016) in expansion states 
relative to nonexpansion states. Similarly, among black 
men, the DID analysis showed an increase in inter-
mediate-risk or low-risk disease when comparing all 
pre-Medicaid expansion and post-Medicaid expansion 
years for changes that approached significance (2.44%; 
95% CI, −0.05% to 4.48%; P = .055) (Table 2). The 
adjusted DID comparing year 3 of expansion alone with 
the pre-Medicaid expansion era showed a significant 
increase of 3.31% (95% CI, 0.32%-6.30%; P = .016) 
in expansion states relative to nonexpansion states.
Finally, we assessed trends in the presentation of 
metastatic disease at diagnosis. From the pre-Medicaid 
expansion era to the post-Medicaid expansion era, the 
unadjusted proportion of men presenting with metastatic 
disease at diagnosis increased in both expansion states 
(from 4.2% to 6.9%) and nonexpansion states (from 
4.5% to 6.9%) during 2012 through 2016 (Fig. 2D). 
There was no significant DID when comparing pre- 
Medicaid expansion years versus all post-Medicaid expan-
sion years (P = .4) or comparing pre-Medicaid expansion 
years versus year 3 of expansion (P = .4) (Table 1). These 
results were similar among black men (P = .3 and P = .9, 
respectively) (Table 2).
Sensitivity Analyses
Men who were excluded from the primary analysis dif-
fered only marginally in terms of sociodemographic 
variables from those who were included (see Supporting 
Table 4). A sensitivity analyses including these excluded 
men demonstrated similar DIDs for PSA ≥20 ng/mL for 
the entire cohort (DID, −1.76%; 95% CI, −2.65% to 
TABLE 1. Adjusted Difference-in-Difference Analysis for All Men With Prostate Cancera
Outcome at Diagnosis
Post-Medicaid Expansion Years 
Combined: 2015-2016




DID (95% CI), % P DID (95% CI), % P DID(95% CI), % P
PSA >20 ng/mL −2.33 (−3.21, −1.44) <.001b −1.73 (−2.81, 0.65) .002b −2.95 (−4.03, −1.86) <.001b
Intermediate or low risk 0.99 (−0.07, 2.05) .067 0.38 (−0.91, 1.67) .6 1.60 (0.30-2.91) .016b
High risk −1.25 (−2.26, −0.25) .015b −0.63 (−1.86, 0.59) .3 −1.88 (−3.12, −0.64) .003b
Metastatic 0.26 (−0.26, 0.78) .3 0.26 (−0.38, 0.90) .4 0.26 (−0.38, 0.90) .4
Abbreviations: DID, difference-in-difference; PSA, prostate-specific antigen.
aDID values were calculated using multivariable linear regression with an interaction term between a time variable for pre-Medicaid expansion and post-Medicaid 
expansion and patient residence in a state that did or did not expand Medicaid. All covariates in Supporting Table 1, from age to regional high-school attainment, 
were included in each regression.
bThese P values indicate statistical significance.
TABLE 2. Adjusted Difference-in-Difference Analysis for Black Men With Prostate Cancera
Outcome at Diagnosis
Post-Medicaid Expansion Years 
Combined: 2015-2016




DID (95% CI), % P DID (95% CI), % P DID (95% CI), P
PSA >20 ng/mL −3.11 (−5.25, −0.96) .005b −1.76 (−4.36, 0.85) .186 −4.51 (−7.13, −1.88) .001b
Intermediate or low risk 2.40 (−0.05, 4.84) .055 1.52 (−1.44, 4.48) .3 3.31 (0.32-6.30) .030b
High risk −2.05 (−4.36, 0.27) .083 −0.73 (−3.53, 2.07) .6 −3.42 (−6.25, −0.59) .018b
Metastatic −0.36 (−1.69, 0.98) .6 −0.79 (−2.41, 0.82) .3 0.10 (−1.54, 1.73) 0.9
Abbreviations: DID, difference-in-difference; PSA, prostate-specific antigen.
aDID values were calculated using multivariable linear regression with an interaction term between a time variable for pre-Medicaid expansion and post-Medicaid 
expansion and patient residence in a state that did or did not expand Medicaid. All covariates listed in Supporting Table 1, from age to regional high-school attain-
ment, were included in each regression.
bThese P values indicate statistical significance.
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−0.89%; P < .001) and black men (DID, −2.30%; 95% 
CI, −4.37% to −0.823%; P  =  .030) (see Supporting 
Table 5).
Trends in Insurance Coverage
From Census data we found a similar magnitude change 
in insurance coverage for men age 18 to 64  years in 
expansion states relative to nonexpansion states over 
our study period (Crude DID: −1.1%) (see Supporting 
Fig. 1). A similar trend was noted among men with PCa 
in the NCDB (adjusted DID, −0.38%; 95% CI, −0.78 
to 0.01; P = .061) (see Supporting Fig. 2).
DISCUSSION
We sought to measure the correlation between Medicaid 
expansion and access to PCa screening by assessing the 
proportion of men presenting with a high-risk PSA level 
(≥20 ng/mL) at the time of PCa diagnosis, which is as-
sociated with a greater risk of disease recurrence after PCa 
treatment and worse survival after a PCa diagnosis.8,13 By 
using a multivariable DID approach comparing PSA val-
ues between men in expansion and nonexpansion states, 
we observed that Medicaid expansion was associated with 
decreases in the proportion of men presenting with PSA 
≥20  ng/mL, a surrogate for disease with a high-risk of 
recurrence after treatment.12-14 Similarly, we also noted a 
decrease in the proportion of men presenting with high-
risk disease in expansion states relative to nonexpansion 
states.
These results are encouraging given the multitude 
of studies demonstrating sociodemographic disparities 
in PCa outcomes.18-21 Previous work from popula-
tion-based data in the United States noted that men with 
any insurance were much less likely than men without 
any insurance to present with metastatic disease at the 
time of PCa diagnosis.21 Additional prior work from 
the NCDB demonstrated that men aged <65 years who 
had Medicaid insurance were more likely to present 
with metastatic disease compared those who had pri-
vate insurance.20 In the NCDB, Medicaid expansion 
was not associated with changes in the proportion of 
men with newly diagnosed PCa presenting with met-
astatic disease. However, this was not surprising based 
on large screening trials, which showed that reductions 
in metastatic disease at diagnosis took 4 to 6 years after 
randomization.22,23 Meanwhile, reductions in the num-
ber of men presenting with high-risk PSA ≥20 ng/mL 
were seen after only 2 rounds of screening,8 and signif-
icant increases in intermediate-risk or low-risk disease 
were seen within 3 years of randomization.23
In the United States, decreases in the proportion 
of men with PCa presenting with PSA ≥20 ng/mL and 
high-risk PCa in Medicaid expansion states may reflect 
improvements in access to health care and PCa screen-
ing. Thus lower PSA levels and less high-risk disease at 
diagnosis in the first few years after expansion may pre-
cede decreases in incident de novo metastatic disease 
in expansion states and decreases in death from PCa. 
Importantly, however, the greatest impact of Medicaid 
expansion would likely take place in states with the high-
est incidence of PCa-related deaths. As demonstrated 
by Mokdad et al, the states with the highest incidence 
of PCa-related deaths are concentrated in the southeast 
United States and include Mississippi, Alabama, Georgia, 
and South Carolina.24 Notably, these states still have not 
expanded Medicaid (Fig. 1), suggesting that our findings 
actually may underestimate the potential positive impact 
of Medicaid expansion on PCa outcomes because states 
with the worst outcomes did not expand.
In addition, during the study period, PCa screen-
ing practice patterns were likely influenced by the 
US Preventive Services Task Force 2012 guidelines, 
which recommended against any routine PCa screen-
ing.25,26 Since then, the US Preventive Services Task 
Force has assigned a grade C recommendation to PCa 
screening for men aged 55 to 69  years after a shared 
decision-making conversation between patients and 
clinicians.27 With potentially increased acceptance of 
PCa screening related to these new guidelines and in-
creases in young men with health insurance in expan-
sion states, as demonstrated by our analysis of Census 
data, Medicaid expansion states may continue to see 
improvements in PSA levels, and potentially disease 
stage, at PCa diagnosis.
In subgroup analyses, PSA and high-risk disease at 
diagnosis also decreased among black men residing in 
expansion states relative to those in nonexpansion states. 
This indicates that Medicaid expansion may help reduce 
PCa outcome disparities among vulnerable racial groups, 
consistent with previous work.17,28,29 Previous work has 
noted that men with PCa and insurance more often re-
ceive definitive treatment and have improved cancer- 
specific survival.21,30 However, even among men with 
health insurance, those with Medicaid are less likely than 
those with private insurance to receive definitive treat-
ment for PCa.20 Thus future work should assess the as-
sociation between Medicaid expansion and access to PCa 
treatment for men in vulnerable populations. Notably, 
however, Medicaid expansion only applies to men aged 
<65 years, suggesting that further work and interventions 
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will be needed to reduce racial outcome disparities after 
a PCa diagnosis that largely may be caused by differences 
in health care access.31
Our study is not without limitations. The NCDB 
is not a population-based data set; therefore, its trends 
are reflective of the hospital patient population within 
the database, and most hospitals within this data set 
are academic or comprehensive treatment centers (see 
Supporting Table 1). Comparisons to non-NCDB co-
horts have shown that hospitals included in the NCDB 
comprise different proportions of hospitals by state, are 
less likely to represent critical access hospitals or rural 
hospitals, and may offer more cancer-related services.32 
The NCDB is also limited by the variables it captures, 
thus we cannot account for any unmeasured relevant 
factors. Follow-up for this study was relatively short 
after Medicaid expansion, and ongoing study is war-
ranted to discern the downstream effects on PCa out-
comes, including survival and incidence rates. In data 
from a large screening trial in Europe, up to 6  years 
were required to see reductions in incident metastatic 
disease, and up to 8  years were required before there 
were reductions in death from PCa.23,33 Although our 
data suggest that Medicaid expansion improved access 
to optimal PCa care, as measured by disease risk at the 
time of diagnosis, we did not assess actual screening 
rates in expansion states. Previous work has suggested 
that screening did not change in expansion states by 
2015, but these data require longer follow-up.34 Finally, 
although our analysis of insurance coverage does sug-
gest that Medicaid expansion resulted in more men 
with health insurance, our analysis of Census data 
included all men aged 18 to 64  years regardless of 
cancer diagnosis, and our analysis within the NCDB 
included men who already had been diagnosed with 
PCa. A more thorough insurance analysis on the subject 
of PCa screening would assess men in the screening age 
range without a prior diagnosis of PCa.
In the context of these limitations, to our knowl-
edge, our study is the first to assess changes in PSA values 
at the time of PCa diagnosis after statewide Medicaid ex-
pansion on January 1, 2014. In the years after Medicaid 
expansion, there was a decrease in men presenting with 
high-risk PSA values at diagnosis, suggesting an increase 
in access to PCa screening in expansion states. However, 
we suspect that, with longer follow-up, Medicaid expan-
sion may result in decreases in the diagnosis of metastatic 
disease and PCa death, as observed in PCa screening tri-
als with improved access to screening.23 In addition, fu-
ture work should be directed at assessing the effects of 
Medicaid expansion on vulnerable populations, such men 
of African heritage.
FUNDING SUPPORT
This work was supported in part by National Institutes of Health grant 
5U01CA196390 and the Prostate Cancer Foundation (Edward M. 
Schaeffer); the 2019 Urology Care Foundation Residency Research Award 
Program and the Russell Scott, Jr, MD, Urology Research Fund (Adam B. 
Weiner); and the Frederick J. and Theresa Dow Wallace Fund of the New 
York Community Trust (Jim C. Hu).
CONFLICT OF INTEREST DISCLOSURES
The authors made no disclosures.
AUTHOR CONTRIBUTIONS
Adam B. Weiner: Conception and design, acquisition of data, analysis and 
interpretation of data, writing–initial draft, critical revision of the article for 
important intellectual content, statistical analysis, and obtaining funding. 
Amanda X. Vo: Conception and design, acquisition of data, analysis and 
interpretation of data, and writing–initial draft. Anuj S. Desai: Analysis 
and interpretation of data, writing–initial draft, and critical revision of the 
article for important intellectual content. Jim C. Hu: Analysis and inter-
pretation of data, writing–initial draft, and critical revision of the article 
for important intellectual content. Daniel E. Spratt: Analysis and inter-
pretation of data, writing–initial draft, and critical revision of the article 
for important intellectual content. Edward M. Schaeffer: Conception and 
design; analysis and interpretation of data; writing–initial draft; critical 
revision of the article for important intellectual content; obtaining funding; 
administrative, technical, or material support; and supervision.
REFERENCES
 1. Miller DC, Litwin MS, Bergman J, et al. Prostate cancer severity 
among low income, uninsured men. J Urol. 2009;181:579-583; discus-
sion 583-574.
 2. Fedewa SA, Etzioni R, Flanders WD, Jemal A, Ward EM. Association 
of insurance and race/ethnicity with disease severity among men di-
agnosed with prostate cancer, National Cancer Database 2004-2006. 
Cancer Epidemiol Biomarkers Prev. 2010;19:2437-2444.
 3. Ellis L, Canchola AJ, Spiegel D, Ladabaum U, Haile R, Gomez SL. 
Trends in cancer survival by health insurance status in California from 
1997 to 2014. JAMA Oncol. 2018;4:317-323.
 4. Miller S, Wherry LR. Health and access to care during the first 2 years 
of the ACA Medicaid expansions. N Engl J Med. 2017;376:947-956.
 5. Han X, Zhao J, Ruddy KJ, Lin CC, Sineshaw HM, Jemal A. The im-
pact of dependent coverage expansion under the Affordable Care Act 
on time to breast cancer treatment among young women. PLoS One. 
2018;13:e0198771.
 6. Jemal A, Lin CC, Davidoff AJ, Han X. Changes in insurance coverage 
and stage at diagnosis among nonelderly patients with cancer after the 
Affordable Care Act. J Clin Oncol. 2017;35:3906-3915.
 7. Fedewa SA, Yabroff KR, Smith RA, Goding Sauer A, Han X, Jemal A. 
Changes in breast and colorectal cancer screening after Medicaid ex-
pansion under the Affordable Care Act. Am J Prev Med. 2019;57:3-12.
 8. Hugosson J, Roobol MJ, Mansson M, et al. A 16-year follow-up of 
the European Randomized Study of Screening for Prostate Cancer. Eur 
Urol. 2019;76:43-51.
 9. Roobol MJ, Grenabo A, Schroder FH, Hugosson J. Interval cancers in 
prostate cancer screening: comparing 2- and 4-year screening intervals 
in the European Randomized Study of Screening for Prostate Cancer: 
Gothenburg and Rotterdam. J Natl Cancer Inst. 2007;99:1296-1303.
 10. Winchester DP, Stewart AK, Bura C, Jones RS. The National Cancer 
Data Base: a clinical surveillance and quality improvement tool. J Surg 
Oncol. 2004;85:1-3.
 11. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J 
Clin. 2016;66:7-30.
Original Article
3236 Cancer  July 15, 2020
 12. Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate Cancer, 
Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. 
J Natl Compr Canc Netw. 2019;17:479-505.
 13. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. 
Biochemical (prostate specific antigen) recurrence probability follow-
ing radical prostatectomy for clinically localized prostate cancer. J Urol. 
2003;169:517-523.
 14. Faisal FA, Sundi D, Pierorazio PM, et al. Outcomes of men with an 
elevated prostate-specific antigen (PSA) level as their sole preoperative 
intermediate- or high-risk feature. BJU Int. 2014;114:E120-E129.
 15. Edge SB, Byrd DR, Compton CC, Fritz AG, Green FI, Trotti A, eds. 
AJCC Cancer Staging Manual. 7th ed. Springer; 2010.
 16. Dimick JB, Ryan AM. Methods for evaluating changes in health care pol-
icy: the difference-in-differences approach. JAMA. 2014;312:2401-2402.
 17. DeSantis CE, Siegel RL, Sauer AG, et al. Cancer statistics for African 
Americans, 2016: progress and opportunities in reducing racial dispar-
ities. CA Cancer J Clin. 2016;66:290-308.
 18. DeRouen MC, Schupp CW, Yang J, et al. Impact of individual and 
neighborhood factors on socioeconomic disparities in localized and ad-
vanced prostate cancer risk. Cancer Causes Control. 2018;29:951-966.
 19. Hoffman RM, Gilliland FD, Eley JW, et al. Racial and ethnic differ-
ences in advanced-stage prostate cancer: the Prostate Cancer Outcomes 
Study. J Natl Cancer Inst. 2001;93:388-395.
 20. Mahal AR, Mahal BA, Nguyen PL, Yu JB. Prostate cancer outcomes 
for men aged younger than 65 years with Medicaid versus private 
insurance. Cancer. 2018;124:752-759.
 21. Mahal BA, Aizer AA, Ziehr DR, et al. The association between in-
surance status and prostate cancer outcomes: implications for the 
Affordable Care Act. Prostate Cancer Prostatic Dis. 2014;17:273-279.
 22. Schroder FH, Hugosson J, Carlsson S, et al. Screening for prostate can-
cer decreases the risk of developing metastatic disease: findings from 
the European Randomized Study of Screening for Prostate Cancer 
(ERSPC). Eur Urol. 2012;62:745-752.
 23. Buzzoni C, Auvinen A, Roobol MJ, et al. Metastatic prostate cancer 
incidence and prostate-specific antigen testing: new insights from the 
European Randomized Study of Screening for Prostate Cancer. Eur 
Urol. 2015;68:885-890.
 24. Mokdad AH, Dwyer-Lindgren L, Fitzmaurice C, et al. Trends and pat-
terns of disparities in cancer mortality among US counties, 1980-2014. 
JAMA. 2017;317:388-406.
 25. Drazer MW, Huo D, Eggener SE. National prostate cancer screening 
rates after the 2012 US Preventive Services Task Force recommendation 
discouraging prostate-specific antigen-based screening. J Clin Oncol. 
2015;33:2416-2423.
 26. Moyer VA, US Preventive Services Task Force. Screening for prostate 
cancer: U.S. Preventive Services Task Force recommendation state-
ment. Ann Intern Med. 2012;157:120-134.
 27. US Preventive Services Task Force, Grossman DC, Curry SJ, et al. 
Screening for prostate cancer: US Preventive Services Task Force rec-
ommendation statement. JAMA. 2018;319:1901-1913.
 28. Weiner AB, Matulewicz RS, Tosoian JJ, Feinglass JM, Schaeffer EM. 
The effect of socioeconomic status, race, and insurance type on newly 
diagnosed metastatic prostate cancer in the United States (2004-2013). 
Urol Oncol. 2018;36:91.e91-91.e96.
 29. Ramirez E, Morano J, Beguiristain T, et al. Insurance status as a 
modifier of the association between race and stage of prostate can-
cer diagnosis in Florida during 1995 and 2013. Cancer Epidemiol. 
2019;59:104-108.
 30. Gray PJ, Lin CC, Cooperberg MR, Jemal A, Efstathiou JA. Temporal 
trends and the impact of race, insurance, and socioeconomic sta-
tus in the management of localized prostate cancer. Eur Urol. 
2017;71:729-737.
 31. Dess RT, Hartman HE, Mahal BA, et al. Association of black race 
with prostate cancer-specific and other-cause mortality. JAMA Oncol. 
2019;5:975-983.
 32. Bilimoria KY, Bentrem DJ, Stewart AK, Winchester DP, Ko CY. 
Comparison of Commission on Cancer-approved and -nonapproved 
hospitals in the United States: implications for studies that use the 
National Cancer Data Base. J Clin Oncol. 2009;27:4177-4181.
 33. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and pros-
tate-cancer mortality in a randomized European study. N Engl J Med. 
2009;360:1320-1328.
 34. Pucheril D, Zlatev DV, Mossanen M, et al. Impact of late Medicaid 
expansion on prostate cancer screening. J Clin Oncol. 2018;36:141-141.
